Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:HIMS NYSE:NVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHIMSHims & Hers Health$37.24+5.9%$29.69$13.74▼$70.43$8.62B2.3528.45 million shs14.40 million shsNVONovo Nordisk A/S$50.56+3.0%$45.80$35.12▼$71.79$225.77B0.7718.84 million shs10.30 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHIMSHims & Hers Health+2.16%-2.89%+30.87%+43.44%-32.39%NVONovo Nordisk A/S-0.33%-0.97%+11.88%+20.38%-28.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHIMSHims & Hers Health$37.24+5.9%$29.69$13.74▼$70.43$8.62B2.3528.45 million shs14.40 million shsNVONovo Nordisk A/S$50.56+3.0%$45.80$35.12▼$71.79$225.77B0.7718.84 million shs10.30 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHIMSHims & Hers Health+2.16%-2.89%+30.87%+43.44%-32.39%NVONovo Nordisk A/S-0.33%-0.97%+11.88%+20.38%-28.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHIMSHims & Hers Health 2.19Hold$30.70-17.56% DownsideNVONovo Nordisk A/S 2.13Hold$65.5629.66% UpsideCurrent Analyst Ratings BreakdownLatest NVO and HIMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/13/2026HIMSHims & Hers Health Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold7/13/2026NVONovo Nordisk A/S Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/9/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$36.00 ➝ $37.007/6/2026NVONovo Nordisk A/S HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold7/1/2026HIMSHims & Hers Health Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $40.007/1/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$25.00 ➝ $36.006/19/2026NVONovo Nordisk A/S Nordea Equity ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy6/17/2026HIMSHims & Hers Health BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$29.00 ➝ $39.006/8/2026HIMSHims & Hers Health Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/26/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$28.00 ➝ $25.005/22/2026HIMSHims & Hers Health UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$23.00(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHIMSHims & Hers Health$2.35B3.67$0.91 per share41.08$2.38 per share15.65NVONovo Nordisk A/S$46.80B4.82$4.81 per share10.51$6.58 per share7.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHIMSHims & Hers Health$128.37M-$0.09N/A71.6196.75-0.56%6.10%1.52%8/10/2026 (Estimated)NVONovo Nordisk A/S$15.51B$4.2611.8715.464.5037.23%63.31%22.19%8/5/2026 (Estimated)Latest NVO and HIMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026HIMSHims & Hers Health-$0.07N/AN/AN/A$691.65 millionN/A8/5/2026Q2 2026NVONovo Nordisk A/S$0.82N/AN/AN/A$10.99 billionN/A5/11/2026Q1 2026HIMSHims & Hers Health$0.04-$0.40-$0.44-$0.40$616.84 million$608.10 million5/6/2026Q1 2026NVONovo Nordisk A/S$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHIMSHims & Hers HealthN/AN/AN/AN/AN/ANVONovo Nordisk A/S$1.753.46%+21.74%41.08%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHIMSHims & Hers Health2.181.691.56NVONovo Nordisk A/S0.590.790.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHIMSHims & Hers Health63.52%NVONovo Nordisk A/S11.54%Insider OwnershipCompanyInsider OwnershipHIMSHims & Hers Health11.76%NVONovo Nordisk A/S0.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHIMSHims & Hers Health2,442231.46 million204.24 millionOptionableNVONovo Nordisk A/S69,5054.47 billion4.46 billionOptionableNVO and HIMS HeadlinesRecent News About These CompaniesRHHBY's Gazyva Gets FDA Priority Review for Label ExpansionJuly 15 at 1:10 PM | zacks.comNovo Nordisk Expands Cardiometabolic Reach With New Heart Failure–Obesity TrialJuly 15 at 12:51 PM | tipranks.comNovo Nordisk wins EU approval for Wegovy weight-loss pillJuly 15 at 12:40 PM | reuters.comIndia's Sun Pharma wins South Africa approval to launch generic OzempicJuly 15 at 12:00 PM | reuters.comCellular Intelligence Expands Leadership Team with Seasoned AI and Biotech Industry ExecutivesJuly 15 at 9:21 AM | finance.yahoo.comNovo Nordisk A/S (NYSE:NVO) Downgraded to "Strong Sell" Rating by Zacks ResearchJuly 15 at 6:23 AM | marketbeat.comIt's been three months since Lilly launched its obesity pill. Most people are taking Novo's pill instead.July 14 at 8:00 PM | wsj.comFresh off buyout, Akero execs reunite to advance long-acting psoriasis pillJuly 14 at 2:11 PM | biopharmadive.comBNovo Nordisk (CPSE:NOVO B) Reports Fresh Hemophilia Trial Wins In Adults And ChildrenJuly 14 at 2:11 PM | finance.yahoo.comIs This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?July 14 at 9:11 AM | fool.comNovo Nordisk signs pact to assess semaglutide implantJuly 14 at 9:11 AM | just-food.comJNovo Nordisk A/S - share repurchase programmeJuly 13 at 2:02 PM | finance.yahoo.comNovo Nordisk Ramps Up Share Buybacks Under DKK 15 Billion ProgrammeJuly 13 at 1:31 PM | tipranks.comTevis Investment Management Has $2.81 Million Holdings in Novo Nordisk A/S $NVOJuly 13 at 6:07 AM | marketbeat.comCORDA Investment Management LLC. Makes New Investment in Novo Nordisk A/S $NVOJuly 13 at 4:07 AM | marketbeat.comNovo Nordisk A/S $NVO Position Trimmed by Carnegie Investment CounselJuly 13 at 3:59 AM | marketbeat.comNovo Nordisk A/S (NYSE:NVO) Receives Average Recommendation of "Hold" from BrokeragesJuly 12 at 4:28 PM | marketbeat.comKornitzer Capital Management Inc. KS Has $4.01 Million Position in Novo Nordisk A/S $NVOJuly 12 at 12:47 PM | marketbeat.comNovo Nordisk A/S $NVO Position Reduced by Equitable Trust Co.July 12 at 11:04 AM | marketbeat.comnovo nordisk a/s - NVOJuly 11, 2026 | foxbusiness.comA tiny GLP-1 implant is the latest bet to help patients maintain their weight lossJuly 11, 2026 | cnbc.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026Could a Tesla-SpaceX Merger Be Closer Than Investors Think?By Sam Quirke | June 17, 2026As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the WinnerBy Jessica Mitacek | July 6, 2026NVO and HIMS Company DescriptionsHims & Hers Health NYSE:HIMS$37.24 +2.09 (+5.94%) Closing price 03:59 PM EasternExtended Trading$37.08 -0.16 (-0.44%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.Novo Nordisk A/S NYSE:NVO$50.56 +1.49 (+3.04%) Closing price 03:59 PM EasternExtended Trading$50.54 -0.02 (-0.05%) As of 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings Why ASML’s AI Monopoly Is Still Getting Stronger Alphabet’s AI Spending Question Looms Over Q2 Earnings CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks 2 Quantum Stocks That Could Challenge IonQ’s Leadership 3 Small-Cap Stocks Trading Under $10 With Room to Run Plot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-Merger Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
